bachelorThesis
Análisis costo-efectividad de Ocrelizumab para el manejo de Esclerosis Múltiple
Autor
Borras Osorio, Mariana
Prieto Soler, Andrea Carolina
Institución
Resumen
Background: Multiple Sclerosis (MS) is a central nervous system demyelinating disease, of autoimmune etiology. Although it is considered a rare disease, it is the first cause of non-traumatic neurological disability in young adults, and generates high costs for Health Systems. Objectives: Carry out a cost-effectiveness analysis of Ocrelizumab as a treatment for Relapsing-Remitting MS with in Colombian health system. Methods: The probabilities of the safety and efficacy outcomes for the different treatment alternatives available for Relapsing-Remitting MS in Colombia, were obtain by an overview literature review. The costs were obtained from the Medicine Thermometer tool of the Colombian Ministry of Health, and from the SOAT rate manual. Results: The most cost-effective therapies for the treatment of Relapsing-Remitting MS in Colombia, were the biologically synthesized drugs (monoclonal antibodies), being Alemtuzumab the most cost-effective, followed by Natalizumab, and then Ocrelizumab. Discussion: Our results differ from what was found by CADTH and NICE analysis, in which they suggest a decrease in the cost of Ocrelizumab, recognizing its effectiveness in the treatment of the athology. Although these interventions correspond to the most cost-effective, the specific choice in the patient treatment must be done individually by the treating physician.